$1,110,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments. Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals. Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility. Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA. Intellectual property reforms to address unfair trade practices in Argentina and Russia. Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act."
You can find more data on corporate lobbying on Quiver Quantitative.
VRTX Congressional Stock Trading
Members of Congress have traded $VRTX stock 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR purchased up to $15,000 on 08/07.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 06/11, 06/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
VRTX Insider Trading Activity
VRTX insiders have traded $VRTX stock on the open market 8 times in the past 6 months. Of those trades, 4 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- RESHMA KEWALRAMANI (CEO & President) has made 2 purchases buying 10,000 shares for an estimated $3,895,767 and 0 sales.
- BRUCE I SACHS has made 2 purchases buying 5,000 shares for an estimated $1,948,415 and 0 sales.
- SANGEETA N. BHATIA has made 0 purchases and 2 sales selling 666 shares for an estimated $305,203.
- JONATHAN BILLER (EVP and Chief Legal Officer) sold 694 shares for an estimated $280,521
- DAVID ALTSHULER (EVP, Chief Scientific Officer) sold 52 shares for an estimated $22,083
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VRTX Hedge Fund Activity
We have seen 674 institutional investors add shares of VRTX stock to their portfolio, and 763 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS added 1,986,004 shares (+305.6%) to their portfolio in Q2 2025, for an estimated $884,168,980
- AMUNDI removed 1,965,643 shares (-63.4%) from their portfolio in Q2 2025, for an estimated $875,104,263
- JPMORGAN CHASE & CO removed 1,886,284 shares (-24.3%) from their portfolio in Q2 2025, for an estimated $839,773,636
- VICTORY CAPITAL MANAGEMENT INC added 1,861,279 shares (+633.3%) to their portfolio in Q2 2025, for an estimated $828,641,410
- CAPITAL RESEARCH GLOBAL INVESTORS added 1,571,947 shares (+10.8%) to their portfolio in Q2 2025, for an estimated $699,830,804
- FMR LLC removed 1,320,812 shares (-17.1%) from their portfolio in Q2 2025, for an estimated $588,025,502
- JENNISON ASSOCIATES LLC added 1,089,063 shares (+21.5%) to their portfolio in Q2 2025, for an estimated $484,850,847
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VRTX Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/02/2025
- Leerink Partners issued a "Outperform" rating on 09/25/2025
- Evercore ISI Group issued a "Outperform" rating on 09/11/2025
- Guggenheim issued a "Buy" rating on 08/06/2025
- UBS issued a "Buy" rating on 08/05/2025
- BMO Capital issued a "Outperform" rating on 08/05/2025
- Cantor Fitzgerald issued a "Overweight" rating on 08/05/2025
To track analyst ratings and price targets for VRTX, check out Quiver Quantitative's $VRTX forecast page.
VRTX Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 18 analysts offer price targets for $VRTX in the last 6 months, with a median target of $476.5.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $438.0 on 10/10/2025
- Jessica Fye from JP Morgan set a target price of $530.0 on 10/08/2025
- Geoff Meacham from Citigroup set a target price of $575.0 on 10/02/2025
- David Risinger from Leerink Partners set a target price of $456.0 on 09/25/2025
- Liisa Bayko from Evercore ISI Group set a target price of $475.0 on 09/11/2025
- Mohit Bansal from Wells Fargo set a target price of $460.0 on 08/06/2025
- Whitney Ijem from Canaccord Genuity set a target price of $411.0 on 08/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
